skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer

Abstract

C2ORF40 encodes a secreted protein which is cleaved to generate soluble peptides by proteolytic processing and this process is believed to be necessary for C2ORF40 to exert cell type specific biological activity. Here, we reported a short mimic peptide of human C2ORF40 acts potential therapeutic efficacy in human cancer cells in vitro and in vivo. We synthesized a short peptide of human C2ORF40, named C2ORF40 mimic peptide fragment and assessed its biological function on cancer cell growth, migration and tumorigenesis. Cell growth assay showed that C2ORF40 mimic peptide fragment significantly suppressed cell proliferation of breast and lung cancer cells. Moreover, C2ORF40 mimic peptide fragment significantly inhibited the migration and invasion of breast cancer cells. Furthermore, we showed that this peptide suppressed tumorigenesis in breast tumor xenograft model. Cell cycle assay indicated that the C2ORF40 mimic peptide fragment suppressed the growth of tumor cells through inducing mitotic phase arrest. In conclusion, our results firstly suggested that this short synthetic peptide of human C2ORF40 may be a candidate tumor therapeutic agent.

Authors:
 [1];  [1];  [1];  [2];  [3]
  1. Shandong Univ., Jinan (China)
  2. Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
  3. Shandong Univ. School of Medicine, Jinan (China)
Publication Date:
Research Org.:
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Sponsoring Org.:
USDOE Office of Science (SC), Biological and Environmental Research (BER) (SC-23)
OSTI Identifier:
1408405
DOE Contract Number:  
AC02-05CH11231
Resource Type:
Journal Article
Resource Relation:
Journal Name: Oncotarget; Journal Volume: 8; Journal Issue: 26
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES

Citation Formats

Lin, Chaoyang, Zhang, Pengju, Jiang, Anli, Mao, Jian-Hua, and Wei, Guangwei. A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer. United States: N. p., 2017. Web. doi:10.18632/oncotarget.16713.
Lin, Chaoyang, Zhang, Pengju, Jiang, Anli, Mao, Jian-Hua, & Wei, Guangwei. A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer. United States. doi:10.18632/oncotarget.16713.
Lin, Chaoyang, Zhang, Pengju, Jiang, Anli, Mao, Jian-Hua, and Wei, Guangwei. Thu . "A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer". United States. doi:10.18632/oncotarget.16713.
@article{osti_1408405,
title = {A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer},
author = {Lin, Chaoyang and Zhang, Pengju and Jiang, Anli and Mao, Jian-Hua and Wei, Guangwei},
abstractNote = {C2ORF40 encodes a secreted protein which is cleaved to generate soluble peptides by proteolytic processing and this process is believed to be necessary for C2ORF40 to exert cell type specific biological activity. Here, we reported a short mimic peptide of human C2ORF40 acts potential therapeutic efficacy in human cancer cells in vitro and in vivo. We synthesized a short peptide of human C2ORF40, named C2ORF40 mimic peptide fragment and assessed its biological function on cancer cell growth, migration and tumorigenesis. Cell growth assay showed that C2ORF40 mimic peptide fragment significantly suppressed cell proliferation of breast and lung cancer cells. Moreover, C2ORF40 mimic peptide fragment significantly inhibited the migration and invasion of breast cancer cells. Furthermore, we showed that this peptide suppressed tumorigenesis in breast tumor xenograft model. Cell cycle assay indicated that the C2ORF40 mimic peptide fragment suppressed the growth of tumor cells through inducing mitotic phase arrest. In conclusion, our results firstly suggested that this short synthetic peptide of human C2ORF40 may be a candidate tumor therapeutic agent.},
doi = {10.18632/oncotarget.16713},
journal = {Oncotarget},
number = 26,
volume = 8,
place = {United States},
year = {Thu Mar 30 00:00:00 EDT 2017},
month = {Thu Mar 30 00:00:00 EDT 2017}
}